RE:RE:ONCY Presented Positive GOBLET Pancreatic Cancer Data @ ESMO"The data from this study show a correlation between the expansion of TIL-specific clones and tumor response, which provides compelling support for the use of pelareorep-based therapies in immunologically "cold" tumors. In particular, these data, along with the impressive clinical results, support the ability of pelareorep-checkpoint inhibitor combination therapies to meaningfully improve treatment responses in diseases like pancreatic cancer that have resisted immune-based therapeutic approaches," said Thomas Heineman, M.D., Ph.D., Chief Medical Officer at Oncolytics.
As previously posted the Accelerated Approval Program is a drug development pathway that offers an early approval based on a “surrogate” marker in a clinical trial. A surrogate marker is a biomarker or clinical marker that can be measured at an earlier point in a trial than the type of endpoints that may be used in a traditional approval.
https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-ord-shs?postid=35772881